^
    Back
    Association details:
    Biomarker:FLT3 mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:STI-8591 (FLT3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)

    Excerpt:
    ...Subjects are required to provide FLT3 mutation status testing within 6 months prior to the first dose, and if not, are willing to undergo screening period testing as required by the protocol....
    Trial ID:
    NCT05947344
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2023
    Title:

    5010 STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3-Mutated (mut) Acute Myeloid Leukemia (AML)

    Published date:
    11/02/2023
    Excerpt:
    ...STI-8591, a novel TKI exhibited a potent antileukemic activity in various FLT3 mut AML models, including those carrying FLT3 mut associated with drug resistance.